How Aging Turns Artery Cells Tumor-Like — and What to Do About It
Vascular aging drives smooth muscle cells in plaques to behave like cancer cells. New therapeutic targets could stabilize dangerous arterial plaques.
Summary
Atherosclerotic cardiovascular disease kills millions despite modern treatments. A new review reveals that vascular smooth muscle cells inside arterial plaques undergo a striking transformation — accumulating DNA damage, reprogramming their epigenetics, expanding as clones, and shifting into multiple cell identities, all in ways that eerily resemble cancer biology. Vascular aging is the key driver, impairing DNA repair, triggering cellular senescence, and remodeling the plaque's local environment. The authors propose three therapeutic strategies: restoring DNA damage response machinery, nudging smooth muscle cells toward protective plaque-stabilizing states, and blocking the abnormal tiny blood vessels that grow inside dangerous plaques. Most evidence is still preclinical, but the framework offers a fresh precision-medicine lens for a disease that remains a leading cause of death worldwide.
Detailed Summary
Atherosclerotic cardiovascular disease (ASCVD) is the world's leading killer, and residual cardiovascular risk remains stubbornly high even in patients on optimal lipid-lowering, antithrombotic, and anti-inflammatory therapy. This review argues that the missing piece lies inside the plaque itself — specifically in the behavior of vascular smooth muscle cells (VSMCs), which make up a large fraction of atherosclerotic lesions.
The central insight is that aging vessels push VSMCs through a tumor-like transformation. This does not mean the cells become cancerous, but they adopt convergent pathological programs: genomic instability from accumulated DNA damage, epigenetic reprogramming, clonal selection and expansion, multilineage phenotypic switching (VSMCs morphing into foam-cell-like, macrophage-like, or stem-cell-like states), inflammatory microenvironmental remodeling, and pathological formation of new microvessels inside the plaque. Vascular aging amplifies every step by degrading DNA repair capacity, altering extracellular matrix mechanics, inducing senescence and the senescence-associated secretory phenotype (SASP), and reshaping local selective niches that favor dangerous clones.
The authors map four interconnected mechanisms driving this process: DNA damage accumulation and repair imbalance; epigenetic reprogramming that unlocks normally silenced cell states; clonal expansion coupled with plastic phenotypic transitions; and pathological intraplaque neovascularization that destabilizes the fibrous cap. Each mechanism represents a potential intervention point.
Three corresponding therapeutic axes emerge: preserving genomic stability and DNA damage response signaling; promoting protective fibrous cap states while suppressing harmful clonal and phenotypic trajectories; and using lesion-targeted approaches to inhibit intraplaque angiogenesis. The convergence with cancer biology also suggests that oncology-derived tools — epigenetic editors, senolytic agents, clonal-evolution modeling — could be repurposed for plaque stabilization.
Caveats are significant. Most supporting evidence is preclinical. Stage- and state-specific therapeutic windows remain undefined, and the cellular and spatial heterogeneity of plaques makes uniform targeting difficult. Future clinical translation will require spatially restricted, cell-type-specific delivery strategies.
Key Findings
- Vascular smooth muscle cells in aging arteries acquire tumor-like traits including clonal expansion, DNA instability, and phenotypic plasticity.
- Cellular senescence and SASP are key aging-driven mechanisms that reshape the plaque microenvironment to favor dangerous VSMC states.
- Pathological intraplaque neovascularization, driven by these tumor-like programs, destabilizes the fibrous cap and raises rupture risk.
- Restoring DNA damage response, promoting protective VSMC states, and blocking intraplaque angiogenesis are proposed as three therapeutic axes.
- Cancer-biology tools — epigenetic editors, senolytics, clonal modeling — may translate into next-generation plaque-stabilization strategies.
Methodology
This is a narrative review article published in Ageing Research Reviews, synthesizing current mechanistic evidence on VSMC tumor-like transformation in atherosclerosis. No original experimental data are presented; conclusions are drawn from existing preclinical studies, molecular biology literature, and translational research. The review is hypothesis-generating rather than hypothesis-testing.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. All mechanistic conclusions should be interpreted with that constraint in mind. Nearly all supporting evidence cited in the review is preclinical, limiting immediate clinical application. The therapeutic strategies proposed are conceptual frameworks without defined dosing, targeting strategies, or human trial data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: